Dallas-Fort Worth Metroplex
Sectors:
Min Investment:
Max Investment:
Target Investment:
High School
(1990 - 1994)
2022
2022
2019 - 2022
2019 - 2022
Strategic Marketing, Product Management, Business Development, and Leadership • Lead eight-person team focused on global and upstream marketing, business development for $800MM division • Launched five products including: radiofrequency generator (Ionic RF); software allowing for greater use of MRI, bring your own device patient controllers; first to world remote programming system; and longitudinal patient app (MyPath) • Delivered key elements of strategic plan, evaluation of a changing interventional pain landscape (e.g. shift to minimally invasive surgery), and prioritization of innovation budget across R&D, clinical, and digital to shape next 5-year cadence
2013 - 2019
2017 - 2019
Business Development, Technology Assessment, Development Planning • Led R&D’s external opportunities and partnerships efforts through evaluating technology assessments, developing product roadmaps, outlining multi-year development/clinical/regulatory plans, establishing probability of success, integration plans • Directed and ensured alignment of various functional leaders (e.g. sr. leadership, technical development, clinical, regulatory affairs, legal/intellectual property, transactions, medical affairs, finance) through biweekly external technology reviews • Publicly disclosed transactions include acquisition of Tear Film Innovations, PowerVision, TrueVision and partnership with MOVU; numerous other licensing and equity investments not disclosed • Led R&D wide effort to look at all spending categories and brainstorm and assess opportunities to outsource activities
2015 - 2017
Product design and development, Regulatory planning, and Product launch • Returned and converted the $100MM+ Japan intraocular lens (IOL) portfolio effected by recalls through manufacturing process improvements, that have led to one of Alcon’s highest clarity lens (“A” code) • Achieved CE mark and launched innovative presbyopia and astigmatism correcting IOL, PanOptix Toric, by building development plan, performing equivalence and registration testing, navigating the changing EU MedDev regulations, and working with global and area marketing and supply chain • Awarded Global Alcon Excellence Award for Customer Focus
2014 - 2015
Post-merger integration, Product launch, Manufacturing and Distribution scaling • Led all aspects of integration of WaveTec into Alcon including coordination between 13 functional leads and their teams • Executed on plan to exceed deal model, driven by higher sales, higher pricing, and inclusion of subscription fees • Launched new product, VerifEye+ including modular distribution and established intraoperative aberrometry globally • Increased production capabilities by 3x in 2015 and established scaling plan for up 6x in 2016 • Hired 35+ FTEs and integrating processes across quality, MTO, R&D, and commercial to continue business operations
2013 - 2014
Investor Relations and Financial Performance Reporting • Collaborated across $11B division to provide synopsis of business performance to Novartis CEO, Executive Committee of Novartis, and Board of Directors including shepherding all group level business development and capital spending requests • Wrote and socialized quarterly press releases and supporting Investor Relations documents • Provided analytical guidance to support key business initiatives including business development transactions, strategic planning/budget (e.g. division head challenges), and market dynamics (e.g. market development for cataract, glaucoma) • Led special projects that are cross-functional or cross-divisional in nature (e.g. Animal health collaboration, surgical backorder investigation, vitamins divestment, CEO and Chairman Visits preparations, etc.)
2012 - 2012
2012 - 2012
• Led cross-functional strategic planning process for pre-commercial biopharmaceutical company • Advised functional areas through projects ranging from clinical operations capacity planning to process design • Independent monitoring committee recommended closure of Phase III BEACON trial due to patient safety
2009 - 2012
2011 - 2012
•Managed 4 person strategy and business analytics team •Delivered five year global strategic plan for ~$1.5B Coronary and Renal Denervation business •Developed emerging markets strategy by partnering with local geographies (e.g. China, India, Brazil) and business development to catalyze overall therapy penetration and “value” segment offerings •Roadmapped innovations to sustain core business which included alternative distribution and emerging markets access •Selected as Mentor for participants in the Coronary Leadership Development Program Business Challenge
2009 - 2011
Coronary/Peripheral Pipeline Strategy Clinical Marketing, Business Model Innovation, Corporate Integration • Drove clinical marketing efforts for novel vascular intervention for erectile dysfunction (e.g., market sizing, patient recruitment, development pathway, investigator relationships, outcomes analysis, and prevalence study design) • Oversaw 5 person, international team to evaluate multiple post-acquisition commercialization scenarios (e.g. Invatec) • Oversaw 5 person, international team to evaluate long-term commercialization scenarios post acquisition (e.g. Invatec) • Conducted marketing due diligence for interventional hypertension acquisition and led integration workstreams for agency partnership search, capital equipment policies, and disruptive technology pricing Endovascular Market Development Strategy, Field Implementation, Innovation, Leadership • Generated ~$4M in incremental annual revenue by developing and launching a market development program (Crosshair); designed sales team materials; conducted training program; drove implementation through 15 person team in ~75 accounts • Executed structural changes to therapy development team that led to increased value, visibility, and collaboration; optimized incentives, implemented account metrics, conducted biannual summits, and developed career path ladder • Established, recruited, and managed 8 person advisory board to uncover barriers to diagnosis and brainstorm solutions • Managed two MBA teams that outlined opportunity for 3D pre-case planning (launched in ’09) and handheld ultrasound • Selected for the Medtronic Marketing Leaders (2009) and Endovascular Leadership Development (2009-10) Programs
2007 - 2008
2007 - 2008
Due Diligence, Corporate Strategy, Regionalized Sales & Marketing • Forecasted 10 year potential of cardiac rhythm, drug eluting stent, neuromodulation, heart valves, and ablation markets, evaluated potential synergies and recommended acquisition scenarios based on valuation implications of market trends • Developed region-specific strategies for ~$2B infused biologic to address the changing needs of stakeholders (e.g. physicians, payors, hospitals, infusion providers) faced with different local drivers including payor pressure, pricing, and competitive usage by analyzing usage patterns across ~64 US metro areas and initiating 4 on the ground pilots
2006 - 2006
2006 - 2006
2003 - 2005
2003 - 2005
Field Sales, Product Launch, and Clinical Research • Called on ~20 cardiologists (e.g. EPs) in $30M territory; led clinical and technical training for 20 person sales team • Launched 6 cardiac products through ~20 training programs directed at nurses, physicians, hospital staff, and sales team • Spearheaded study with leading doctor to evaluate benefits of a novel, magnetically guided procedure for heart failure • Directed selection and set-up for ~12 post-market clinical trials at 10 centers in the region
2002 - 2003
2002 - 2003
• Collaborated with MD Anderson to establish effectiveness of proprietary radiopharmaceuticals, obtain ~$2M in NIH grants • Developed process that combined technology from vendors to create 20% more sensitive, 300% longer-lasting detectors
2000 - 2001
2000 - 2001
• Led “firefighting” team to redeploy compensation system for a major technology research firm which aided in collecting $1.6M in past due implementation fees • Recruited, trained, and co-managed a 10 person software division to develop models to price insurance policies